The results show that the constructed CAR-NK can successfully express the affibodies, and CAR-NK with affibodies as extracellular recognition domain have similar function to traditional CAR-NK in killing HER-2 positive breast cancer (Figure 1). Here, ERBB2 is linked to breast carcinoma.